On Monday, Dr Reddy’s Laboratories announced the commercial launch of anti-Covid drug 2DG, developed by Defence Research and Development Organisation (DRDO).
This comes after the DRDO earlier on June 1 said that the anti-covid drug is approved for emergency use as an adjunct therapy to the standard of care in the treatment of coronavirus patients in hospital settings.
The first batch of DRDO’s anti-Covid-19 drug was released on May 17 by Union defence minister Rajnath Singh and health minister Dr. Harsh Vardhan, after the Drugs Controller General of India permitted the emergency use.
The DRDO has advised that pregnant and lactating women and patients below 18 years are not supposed to use the 2DG.
“Ideally, 2DG should be prescribed as early as possible by doctors for moderate to serve Covid patients for a maximum duration of up to 10 days,” it said.
Discussion about this post